Issue link: http://osercommunicationsgroup.uberflip.com/i/1013207
Chain Drugstore Daily 6 1 Monday, August 27, 2018 Chief Executive Officer/Founder of Scimera BioScience, doing business as ScimeraMD. "These new products – Immune MD™ and E2 Energy & Performance™ – have been stringently researched and we're confident that they meet the high criteria of our other products that have been well-received by the marketplace," said Dr. Chaleff. "Clinical studies and independent university research support the efficacy of these products that are available online, at independent pharma- cies and supermarkets nationwide and internationally." ImmuneMD is a physician-formulat- ed product that is comprehensive in maintaining and boosting immune sys- tem functions, according to Dr. Chaleff. The orange-flavored immune booster complex powder can be mixed in water or sprinkled in shakes. The patent-pend- ing product features highly researched immune support ingredients that act syn- ergistically to optimize users' immune systems, health and wellness. "ImmuneMD is designed to provide immune support for travelers, office workers, students, professionals and oth- ers in close contact with people," said Dr. Chaleff. "In addition to these closequar- ter situations, ImmuneMD also delivers year-round immune support for overall health and wellness." The product combines highly absorbable Vitamin C, high-dose chelat- ed zinc, 10 billion CFU of highly researched immuno probiotics, and potent beta glucans such as well-known Wellmune ® +, all ingredients that inde- pendently promote your immune system function. When combined, Dr. Chaleff believes that it is extremely comprehen- sive and recommends it to patients on a ScimeraMD (Cont'd. from p. 1) routine basis. E2 Energy & Performance features the same testing and research guidelines as other Scimera products and has proven to be effective in promoting energy, focus and physical performances. According to Dr. Chaleff, independent clinical studies and university research indicate that users experience a 24 percent immediate increase in muscle performance. The tropical fruit-flavored powder can be mixed in water, drinks, food and popular smoothie shakes. United States Army soldiers, stu- dents, professional athletes and health club members report the effectiveness of this product. About Scimera BioScience ® Scimera Bioscience, doing business as ScimeraMD, develops cutting-edge bio- ceuticals that address cardiovascular, immune system, bone and joint, gastroin- testinal, respiratory and a wide array of health issues. The team includes physi- cians, pharmacists, chemists and con- sumer advocates. The company utilizes the best clinical studies, advanced research and evidence-based data, and strives to promote understanding of dis- ease processes and proactive interven- tion. Products are made in the USA in an FDA-inspected facility that meets the stringent standards of current Good Manufacturing Practices (GMP) and U.S. Pharmacopeia guidelines. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or pre- vent any disease. +Wellmune (WGP) ® is a registered trademark of Kerry Group. For more information, visit booth #4043 or go to www.scimera.com. communication with a dynamic subject line, headline, preheader (preview text), email content and layout. Pharmacists and technicians approach their email as we do. We glance at our inbox and delete emails that do not seem relevant or useful, respond to those that are more time sensitive and flag oth- ers to review at a later time. Therefore, your communication must capture the recipient's attention within just a few sec- onds. The first step of a successful cam- paign is to ensure the email message hits the inbox and not a junk folder. PDQ Communications' 25-plus servers are dedicated to PDQ emails and are not shared servers. In addition, it uses unique IP addresses for all PDQ emails to ensure your message will arrive in the recipi- ent's inbox. Viewability is the second step. By utilizing responsive design HTML, your email will format according to the device used by the recipient, such as a computer, tablet or mobile device. It PDQ Communications (Cont'd. from p. 1) then tests your HTML artwork to see how the message will render on differ- ent platforms and guide you to fix any rendering issues before your actual deployment. PDQ can ramp up your ROI with high open and click-through rates. By adding an echo email to your program, you can increase your analytics without bombarding the recipient. After an email is deployed, for only 50 percent of the cost, it re-deploys, or echoes the same email to the target list, while suppressing openers of the original email. The email plus echo programs have proven success- ful, with open rates averaging 25 percent, significantly higher than the competition. It is so confident in its electronic pro- grams that it guarantees at least a 10 per- cent gross open rate or it will re-deploy for free. Let PDQ be your digital communi- cations partner. It can generate the aware- ness levels you may be missing. Visit PDQ Communications at booth #2301. For more information, call 866.485.4737. connect every storage unit in a single centralized system. This cuts out manual temperature checks, so pharmacists can focus on patients. It's the most efficient and reliable method for maintaining quality standards for medications and drugs. Our wireless sensors and analytics dashboard enable continuous monitoring, ensuring the safety of patients. CDD: Some pharmacies conduct manual checks using pen and paper, providing limited visibility into compliance. Can you tell our readers more about continu- ous monitoring systems? JG: Leading pharmacies are moving to continuous temperature monitoring, a more proactive approach than a paper- based/clipboard system. By combining wireless sensors, real-time data logging and alerts across multiple digital plat- forms and storage units, compliance and operations managers have more visibility into temperature excursions and are able to take the appropriate corrective actions when temperatures fall outside of safe ranges. This ensures the efficacy of vac- cines and prioritizes patient safety. CDD: The CDC updated the Vaccine Storage and Handling Toolkit earlier this year. Can you tell our readers more about it? JG: The purpose of the Vaccine and Storage Handling Toolkit is to fully ensure the safety of vaccines. To do that, digital data loggers (DDL) or sensors for each unit is required. These sensors need to record temperatures at 15-minute intervals – a difficult task if you are using SmartSense (Cont'd. from p. 1) manual methods. A buffered temperature probe to precisely measure vaccine tem- perature is recommended. The difference between ambient temperature and prod- uct temperature can vary widely, so a more accurate way of measuring product temperature is necessary. CDD: How is SmartSense addressing these CDC vaccine recommendations? JG: In addition to automated tempera- ture monitoring and compliance logging, our product line includes both physical and virtual buffer vials for product tem- perature simulation. Our pharmacy solu- tions exceed CDC pharmacy require- ments – and more. For example, the ther- modynamic principles of our Virtual Buffer Vials significantly advance on typical glycol buffer vials. Not only do they save much-needed space within units, but more importantly, they improve the accuracy of temperature monitoring and provide data logs, which are required by some state boards of pharmacy. CDD: What's coming up for you a little farther down the road? JG: We plan to expand on our product simulation profiles, but right now we're refining our current buffer vial solutions. We are always looking to offer the most advanced temperature monitoring sys- tem, and doing so requires close collabo- ration with pharmacies to understand their needs. For more information, visit booth #3813, go to www.smartsense.co, call 866.806.2653 or email digisolutionsupport @digi.com. seamlessly connects to the CONTOUR DIABETES app, a mobile app that col- lects, stores and analyzes patient blood glucose measurements received from the meter. The system combines the remark- able accuracy of the CONTOUR NEXT ONE meter with the easy-to-use features of the CONTOUR DIABETES app and is designed to provide insights that may help people manage their diabetes in an organized fashion. These insights are par- ticularly useful for the person with dia- betes and their healthcare professional because they are based upon the data col- lected from the meter, which has been shown to be highly accurate. In the management of diabetes, the accuracy and quality of an individual's blood glucose data are important. Being able to easily access highly accurate blood glucose data can create significant value for patients and healthcare profes- sionals, as they monitor and manage dia- betes. CONTOUR NEXT ONE is the most accurate system developed by Ascensia Diabetes Care to date and has been shown to deliver remarkable accuracy, with 95 percent of results within ±8.4 mg/dL or ±8.4 percent of the laboratory reference values for glucose concentra- tions < 100 mg/dL or ≥ 100 mg/dL, respectively, when tested in subjects with diabetes via fingerstick results. The meter also includes features CONTOUR (Cont'd. from p. 1) specifically designed to meet patient needs, including the smartLIGHT feature and Second-Chance ® Sampling. The smartLIGHT color indicator gives instant feedback on blood glucose results, compar- ing the actual results with target levels and illuminating green for within target range, yellow for above target range and red for below target range. The light also shows successful pairing between meter and app and can be used for low-light testing. Second-Chance sampling may help minimize waste by giving patients 60 seconds to reapply blood to the same test strip. The meter prompts blood to be reapplied to the same strip if there is not enough the first time. With the highly accurate results demonstrated by the CONTOUR NEXT ONE and their easy access in the CON- TOUR DIABETES app, people with dia- betes are now able to gain meaningful insights that may help them understand how certain aspects of their daily activities affect their blood glucose, which has the potential to help to improve how patients are managed. The CONTOUR NEXT ONE meter and CONTOUR NEXT Test Strips are available through commercial insurance, through Medicare Part B or as an affordable over-the-counter cash option, and can be found at all major retailers and independent pharmacies. Sponsored by Ascensia Diabetes Care. For more information, visit booth #920, call 800.348.8100 or go to www .contournext.com.